Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zovegalisib · RLY-2608, ACC-602

Small molecule · Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα, p (PIK3CA) · developed by Relay Therapeutics

Phase 3 Most advanced trial
RLAY Developer
2 Registered trials

What is Zovegalisib?

Zovegalisib is an orally bioavailable, mutant-selective inhibitor of the PI3Kα catalytic subunit encoded by PIK3CA. It allosterically binds mutant forms of PIK3CA, blocking signaling through the PI3K/Akt/mTOR pathway. It is being studied in PIK3CA-related overgrowth and vascular malformation syndromes and in HER2-negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RLY-2608, ACC-602
Drug type
Small molecule
Targets
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα, p (PIK3CA)
Mechanism
Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα, p (PIK3CA)
Pathways
PI3K/Akt/mTOR pathway, apoptosis, growth inhibition
Therapy area
Oncology
Developer
Relay Therapeutics, Inc. (RLAY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
LR5XLA3BPC

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06982521 Phase 3 PIK3CA Mutation Recruiting RLAY
NCT06789913 Phase 2 PIK3CA-Related Overgrowth Spectrum (PROS) Recruiting RLAY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Breast CancerBreast CancerCLOVES SyndromeHER2- Negative Breast CancerHormone Receptor Positive TumorKlippel Trenaunay SyndromeLymphatic MalformationsMetastatic Breast CancerPIK3CA MutationPIK3CA-Related Overgrowth Spectrum (PROS)Vascular AnomaliesVascular Malformations

Other drugs acting on PIK3CA

More from Relay Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RLAY page.

Follow RLAY, the company behind Zovegalisib

See RLAY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RLAY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.